Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741480 | 0.90 | MAOB (0.81) | MAOBAPPCYP19A1RAB9AHRH3 | |
| SCHEMBL18664184 | 0.90 | MAOB (0.81) | MAOBAPPCYP19A1RAB9AHRH3 | |
| SCHEMBL10991891 | 0.86 | MAOB (0.80) | MAOBAPPRAB9ANR4A2MAOA | |
| SCHEMBL11122145 | 0.85 | MAOB (0.56) | MAOBAPPCYP19A1RAB9AMAOA | |
| SCHEMBL16841039 | 0.85 | MAOB (0.72) | MAOBAPPCYP19A1RAB9AHRH3 | |
| SCHEMBL28999638 | 0.82 | NR4A2 (0.58) | MAOBAPPRAB9ANR4A2MAOA | |
| SCHEMBL15038105 | 0.81 | MAOB (0.68) | MAOBAPPRAB9AHRH3MAOA | |
| SCHEMBL16604318 | 0.81 | MAOB (0.68) | MAOBCYP19A1RAB9AHRH3MAOA | |
| SCHEMBL2276512 | 0.81 | MAOB (0.68) | MAOBAPPCYP19A1RAB9AHRH3 | |
| SCHEMBL994803 | 0.81 | MAOB (0.68) | MAOBAPPRAB9AHRH3NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0028305-B1 | DIARYL COMPOUNDS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | claimed |
| EP-0028305-A1 | Diaryl compounds and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-05-13 | — | — | EP | claimed |
| US-20190161439-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-3309145-A1 | MARINE PERIPHYTON REPELLENT COMPOSITION | Basseru Chemical Co., Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | BASSERU CHEMICAL CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288228-B1 | DIAMINOTRIAZINE DERIVATIVES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | disclosed |
| EP-0028305-B1 | DIARYL COMPOUNDS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | disclosed |
| EP-0028305-A1 | Diaryl compounds and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072657-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | CCL11, SPTLC3, C3AR1 | MAOB 2329/4885APP 4609/4885CYP19A1 3007/4885 |
| US-20190161439-A1 | MARINE SESSILE ORGANISM-REPELLING COMPOSITION | CCL11, SPTLC3, C3AR1 | MAOB 2329/4885APP 4609/4885CYP19A1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.